Board Member
Neurocrine Biosciences Inc (NBIX)Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsKyle Gano, Ph.D. is recorded as CEO and Board Member at Neurocrine Biosciences Inc (NBIX) since October 11, 2024. Neurocrine Biosciences Inc reported in an 8-K filed October 11, 2024 that Kyle Gano, Ph.D. was appointed President and Chief Executive Officer, effective October 11, 2024. Neurocrine Biosciences Inc reported in an 8-K filed May 28, 2024 that Kyle Gano, Ph.D. was appointed President and Chief Executive Officer, effective October 11, 2024. Neurocrine Biosciences Inc reported in an 8-K filed May 28, 2024 that Kyle Gano, Ph.D. was appointed Class II director, effective October 11, 2024. Kyle Gano, Ph.D. has spoken on 1 investor event across 1 company, most recently for Neurocrine Biosciences Inc on September 15, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle W. Gano (CEO and Board Member), Matthew C. Abernethy (CFO) and 7 others.
“Pursuant to the Employment Agreement, Dr. Gano will serve as Neurocrine Biosciences’ President and Chief Executive Officer effective October 11, 2024 (the “Effective Date”).”
“On May 28, 2024, Neurocrine announced the appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine's President and Chief Executive Officer, effective as of the Transition Date.”
“That's a great question, very timely at Neurocrin, I know, industry-wide. You know, my view of China is that they are a competitive force, but at the same time, they represent an important source of innovation.”
2024-10-11–present
2024-10-11–present
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2024-10-11–present
